Onset and Progression of Pathologic Atrophy in Huntington Disease: A Longitudinal MR Imaging Study

BACKGROUND AND PURPOSE: Longitudinal MR imaging measures provide an opportunity to track progression in HD before the emergence of clinical symptoms. This may prove useful in assessing disease-modifying treatments. We investigated how caudate and global volumes change as HD progresses from premanifest to early disease. MATERIALS AND METHODS: Forty HD gene-positive individuals and 19 controls underwent serial volumetric MR imaging (baseline, 12 and 27 months; 2 or 3 scans per person). At baseline, 3 patients with HD were premanifest but developed overt motor features during the study, and 37 had early HD. All had dates of motor onset recorded. Caudates, lateral ventricles, and TIVs were measured using semiautomated procedures. Linear mixed models were used to investigate differences between HD and controls in relation to motor onset, controlling for TIV, sex, and age. RESULTS: Extrapolating backwards in time, we found that differences in caudate and ventricular volumes between patients with HD and controls were evident 14 and 5 years, respectively, before motor onset (P < .05). At onset, caudate volume was 2.58 mL smaller than that in controls (P < .0001); ventricular volume was 9.27 mL larger (P < .0001). HD caudate atrophy rates were linear, showed low variability between subjects, and were approximately 10-fold higher than those in controls (P < .001). HD ventricular enlargement rates were variable between subjects, were approximately 4-fold higher than those in controls at onset (P < .001), and accelerated with disease duration (P = .02). CONCLUSIONS: We provide evidence of acceleration of global atrophy in HD with disproportionate caudate involvement. Both caudate and global measures may be of use as early markers of HD pathology.

[1]  Nick C. Fox,et al.  Automated quantification of caudate atrophy by local registration of serial MRI: Evaluation and application in Huntington's disease , 2009, NeuroImage.

[2]  Nick C Fox,et al.  A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. , 2003, Archives of neurology.

[3]  F. Cendes,et al.  Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. , 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[4]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[5]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[6]  S. Dunnett,et al.  Pharmaceutical, cellular and genetic therapies for Huntington's disease. , 2006, Clinical science.

[7]  Jane S. Paulsen,et al.  In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease , 2004, Neurology.

[8]  J. Brandt,et al.  Onset and rate of striatal atrophy in preclinical Huntington disease , 2004, Neurology.

[9]  Nick C Fox,et al.  Whole‐brain atrophy as a measure of progression in premanifest and early Huntington's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[10]  Nick C. Fox,et al.  Defective emotion recognition in early HD is neuropsychologically and anatomically generic , 2008, Neuropsychologia.

[11]  Bruce Fischl,et al.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. , 2008, Brain : a journal of neurology.

[12]  Andrea Ciarmiello,et al.  Distinct Brain Volume Changes Correlating with Clinical Stage, Disease Progression Rate, Mutation Size, and Age at Onset Prediction as Early Biomarkers of Brain Atrophy in Huntington's Disease , 2009, CNS neuroscience & therapeutics.

[13]  Nick C Fox,et al.  Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. , 2001, AJNR. American journal of neuroradiology.

[14]  Elizabeth H. Aylward,et al.  Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease , 2007, Brain Research Bulletin.

[15]  Andrea Ciarmiello,et al.  Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  Jane S. Paulsen,et al.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length , 2004, Clinical genetics.

[17]  Arthur W. Toga,et al.  A Probabilistic Atlas of the Human Brain: Theory and Rationale for Its Development The International Consortium for Brain Mapping (ICBM) , 1995, NeuroImage.

[18]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[19]  Jane S. Paulsen,et al.  Preparing for preventive clinical trials: the Predict-HD study. , 2006, Archives of neurology.

[20]  Nick C Fox,et al.  Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. , 1997, Computer methods and programs in biomedicine.